Climbazole
CAS 38083-17-9
Climbazole (CAS 38083-17-9) is a Phase 2 pharmaceutical compound with 1 bioactivity target and 0 adverse event associations.
Compound Identity
Matched identifiers and naming fields for the pharmaceutical compound record.
Clinical Development Phase
Highest clinical development phase rendered from the matched compound identifier rows.
Cross-Reference to Cosmetics
Same-CAS ingredient record found in the cosmetics vertical.
Bioactivity & Target Interactions
Target-level activity records with assay counts, activity type, and measured value where present.
| Target | Activity | Value | Assays | Organism |
|---|---|---|---|---|
| - | AC50 | 27553.58235294118 nM | 34 | - |
| - | Potency | 17030.675 nM | 8 | - |
| - | IC50 | 19934 nM | 5 | - |
| Cytochrome P450 3A4 Enzyme |
IC50 | 7 | - | Homo sapiens |
Frequently Asked Questions
Short answers generated only from the same visible source-linked rows on this page.
What is Climbazole used for in pharmaceutical contexts?
Climbazole (CAS 38083-17-9) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.
What are the known adverse events for Climbazole?
No adverse-event association or SIDER side-effect rows are rendered for Climbazole in this page query. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.
Is Climbazole also used in cosmetics?
Yes. The ingredients table has a same-CAS cosmetic profile for Climbazole with EU status "restricted".
What clinical phase is Climbazole in?
Climbazole is rendered with ChEMBL max phase 2.
What bioactivity targets are documented for Climbazole?
Climbazole has 4 bioactivity rows in this page query. Rendered target entries include Cytochrome P450 3A4.